Bio Path Debt
| BPTH Stock | USD 0.80 0.02 2.44% |
Bio Path Holdings holds a debt-to-equity ratio of 0.013. As of now, Bio Path's Short and Long Term Debt Total is decreasing as compared to previous years. The Bio Path's current Debt To Equity is estimated to increase to 0.25, while Net Debt is projected to decrease to (986 K). With a high degree of financial leverage come high-interest payments, which usually reduce Bio Path's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Bio Path's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Bio Path's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Bio Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Bio Path's stakeholders.
For most companies, including Bio Path, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Bio Path Holdings, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Bio Path's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.335 | Book Value 0.714 | Return On Assets (1.40) | Return On Equity (3.66) |
Bio |
Bio Path Bond Ratings
Bio Path Holdings financial ratings play a critical role in determining how much Bio Path have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Bio Path's borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (10.73) | Unlikely Manipulator | View |
Bio Path Holdings Debt to Cash Allocation
As Bio Path Holdings follows its natural business cycle, the capital allocation decisions will not magically go away. Bio Path's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Bio Path Holdings currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Bio Path Holdings has a current ratio of 15.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Bio Path's use of debt, we should always consider it together with its cash and equity.Bio Path Total Assets Over Time
Bio Path Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Bio Path uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Bio Path Debt Ratio | 3.04 |
Bio Path Corporate Bonds Issued
Most Bio bonds can be classified according to their maturity, which is the date when Bio Path Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Bio Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Bio Path Use of Financial Leverage
Understanding the composition and structure of Bio Path's debt gives an idea of how risky is the capital structure of the business and if it is worth investing in it. The degree of Bio Path's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 113 K | 175.6 K | |
| Net Debt | -939 K | -986 K | |
| Short Term Debt | 206 K | 172.6 K | |
| Net Debt To EBITDA | 0.06 | 0.06 | |
| Debt To Equity | 0.23 | 0.25 | |
| Interest Debt Per Share | 0.22 | 0.20 | |
| Debt To Assets | 0.03 | 0.03 | |
| Long Term Debt To Capitalization | (3.27) | (3.43) | |
| Total Debt To Capitalization | 0.19 | 0.18 | |
| Debt Equity Ratio | 0.23 | 0.25 | |
| Debt Ratio | 0.03 | 0.03 | |
| Cash Flow To Debt Ratio | (111.99) | (117.59) |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out the analysis of Bio Path Fundamentals Over Time. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.